Shopping Cart
- Remove All
- Your shopping cart is currently empty
Motixafortide (BKT140 4-fluorobenzoyl) is a CXCR4 antagonist with an IC50 of 1 nM.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $747 | 7-10 days | |
50 mg | $1,190 | 7-10 days |
Description | Motixafortide (BKT140 4-fluorobenzoyl) is a CXCR4 antagonist with an IC50 of 1 nM. |
Targets&IC50 | CXCR4:1 nM |
In vitro | Motixafortide (BKT140) exhibits selective toxicity against AmL and MM cells by specifically inducing CXCR4-dependent and apoptotic cell death in these leukemia and multiple myeloma (MM) cell types. Additionally, treatment with Motixafortide (BKT140) counteracts the IL-6 dependent proliferation and survival observed in ARH77 MM cells. |
In vivo | Treatment with Motixafortide (BKT140) results in reduced size and weight of tumors in animals, alongside increased necrotic areas and elevated apoptotic scores[2]. Additionally, subcutaneous administration of Motixafortide (BKT140) markedly diminishes the growth of human acute myeloid leukemia and multiple myeloma xenografts in a dose-dependent fashion. |
Alias | TF14016, BL-8040, BKT140 (4-fluorobenzoyl) |
Molecular Weight | 2159.52 |
Formula | C97H144FN33O19S2 |
Cas No. | 664334-36-5 |
Relative Density. | 1.52 g/cm3 (Predicted) |
Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||
Solubility Information | DMSO: 36 mg/mL (16.67 mM) | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.